UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 19, 2007
BIOJECT MEDICAL TECHNOLOGIES INC.
(Exact name of registrant as specified in its charter)
Commission File Number: 0-15360
Oregon | | 93-1099680 |
(State or other jurisdiction of incorporation | | (I.R.S. Employer Identification No.) |
or organization) | | |
| | |
20245 SW 95th Avenue | | |
Tualatin, Oregon | | 97062 |
(Address of principal executive offices) | | (Zip Code) |
Registrant’s telephone number, including area code: (503) 692-8001
Former name or former address if changed since last report:
No Change
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
BIOJECT MEDICAL TECHNOLOGIES INC.
FORM 8-K
INDEX
1
Item 1.01 Entry into a Material Definitive Agreement
On December 19, 2007, Bioject and American Stock Transfer & Trust Company entered into an amendment to Bioject’s Rights Agreement. The amendment exempts shareholders affiliated with Partners for Growth, L.P. from the definition of “Acquiring Person” under the Rights Agreement so long as they do not own more than 19.9% of the shares of common stock then outstanding.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
The following exhibits are filed herewith and this list is intended to constitute the exhibit index:
| 4.1 | | Fourth Amendment to Rights Agreement, dated as of November 20, 2007, between Bioject |
| | Medical Technologies Inc. and American Stock Transfer & Trust Company. |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: December 20, 2007 | | BIOJECT MEDICAL TECHNOLOGIES INC. | |
| | (Registrant) | |
| | | |
| | | |
| | /s/ CHRISTINE M. FARRELL | | |
| | Christine M. Farrell | |
| | Vice President of Finance | |
| | (Principal Financial and Accounting Officer) | |
| | | | | |
3
